Quarterly report pursuant to Section 13 or 15(d)

Revenue (Tables)

v3.10.0.1
Revenue (Tables)
 9 Months Ended
Sep. 30, 2018
Revenue from Contract with Customer [Abstract]  
Revenue
During the three and nine months ended September 30, 2018 and 2017, respectively, the Company recognized revenues as follows (in thousands):
 
Three Months Ended September 30,
 
Nine Months Ended September 30,
 
2018
 
2017
 
2018
 
2017
License fees
$
7,873

 
$
3,650

 
$
22,541

 
$
6,166

Research and development services
472

 
263

 
1,555

 
943

Other revenues
—

 
14

 
91

 
14

Total Revenue
$
8,345

 
$
3,927

 
$
24,187

 
$
7,123


During the three and nine months ended September 30, 2018 and 2017, respectively, the Company recognized revenue from the following strategic partnerships and other license agreements (in thousands):
 
Three Months Ended September 30,
 
Nine Months Ended September 30,
 
2018
 
2017
 
2018
 
2017
Seattle Genetics
$
1,788

 
$
—

 
$
4,519

 
$
—

AstraZeneca
5,905

 
2,486

 
14,841

 
3,079

Servier
652

 
474

 
3,279

 
1,163

Other
—

 
967

 
1,548

 
2,881

Total Revenue
$
8,345

 
$
3,927

 
$
24,187

 
$
7,123

Potential Milestone Payments
Under the Company´s existing strategic partnerships, Pieris could receive the following potential milestone payments (in millions):
 
Research, Development & Commercial Milestones
 
Sales Milestones
Seattle Genetics
$
769

 
$
450

AstraZeneca
1,111

 
960

Servier
1,007

 
911

Total potential milestone payments
$
2,887

 
$
2,321